JP2017536116A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536116A5 JP2017536116A5 JP2017525107A JP2017525107A JP2017536116A5 JP 2017536116 A5 JP2017536116 A5 JP 2017536116A5 JP 2017525107 A JP2017525107 A JP 2017525107A JP 2017525107 A JP2017525107 A JP 2017525107A JP 2017536116 A5 JP2017536116 A5 JP 2017536116A5
- Authority
- JP
- Japan
- Prior art keywords
- aav
- nucleic acid
- capsid
- aav capsid
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 51
- 241000702421 Dependoparvovirus Species 0.000 claims 51
- 210000000234 capsid Anatomy 0.000 claims 35
- 108020004707 nucleic acids Proteins 0.000 claims 29
- 102000039446 nucleic acids Human genes 0.000 claims 29
- 150000007523 nucleic acids Chemical class 0.000 claims 29
- 239000002245 particle Substances 0.000 claims 29
- 238000000034 method Methods 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 7
- 210000004248 oligodendroglia Anatomy 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000013607 AAV vector Substances 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021019477A JP2021097675A (ja) | 2014-11-21 | 2021-02-10 | 中枢神経系を標的化したａａｖベクター |
| JP2023108201A JP2023123765A (ja) | 2014-11-21 | 2023-06-30 | 中枢神経系を標的化したａａｖベクター |
| JP2025015920A JP2025072468A (ja) | 2014-11-21 | 2025-02-03 | 中枢神経系を標的化したａａｖベクター |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082897P | 2014-11-21 | 2014-11-21 | |
| US62/082,897 | 2014-11-21 | ||
| US201562218857P | 2015-09-15 | 2015-09-15 | |
| US62/218,857 | 2015-09-15 | ||
| PCT/US2015/061788 WO2016081811A1 (en) | 2014-11-21 | 2015-11-20 | Aav vectors targeted to the central nervous system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019477A Division JP2021097675A (ja) | 2014-11-21 | 2021-02-10 | 中枢神経系を標的化したａａｖベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536116A JP2017536116A (ja) | 2017-12-07 |
| JP2017536116A5 true JP2017536116A5 (OSRAM) | 2018-12-13 |
Family
ID=56014589
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525107A Withdrawn JP2017536116A (ja) | 2014-11-21 | 2015-11-20 | 中枢神経系を標的化したａａｖベクター |
| JP2021019477A Pending JP2021097675A (ja) | 2014-11-21 | 2021-02-10 | 中枢神経系を標的化したａａｖベクター |
| JP2023108201A Pending JP2023123765A (ja) | 2014-11-21 | 2023-06-30 | 中枢神経系を標的化したａａｖベクター |
| JP2025015920A Pending JP2025072468A (ja) | 2014-11-21 | 2025-02-03 | 中枢神経系を標的化したａａｖベクター |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019477A Pending JP2021097675A (ja) | 2014-11-21 | 2021-02-10 | 中枢神経系を標的化したａａｖベクター |
| JP2023108201A Pending JP2023123765A (ja) | 2014-11-21 | 2023-06-30 | 中枢神経系を標的化したａａｖベクター |
| JP2025015920A Pending JP2025072468A (ja) | 2014-11-21 | 2025-02-03 | 中枢神経系を標的化したａａｖベクター |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10532110B2 (OSRAM) |
| EP (2) | EP4344741A3 (OSRAM) |
| JP (4) | JP2017536116A (OSRAM) |
| KR (2) | KR20240063169A (OSRAM) |
| CN (2) | CN107532173A (OSRAM) |
| AU (2) | AU2015349759B2 (OSRAM) |
| BR (1) | BR112017010447A2 (OSRAM) |
| CA (1) | CA2967393A1 (OSRAM) |
| IL (1) | IL252072B (OSRAM) |
| MX (1) | MX2017006652A (OSRAM) |
| RU (1) | RU2727015C2 (OSRAM) |
| WO (1) | WO2016081811A1 (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| MX2017006217A (es) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
| CN107532173A (zh) * | 2014-11-21 | 2018-01-02 | 北卡罗来纳-查佩尔山大学 | 靶向中枢神经系统的aav载体 |
| HK1245326A1 (zh) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | 用於生产scaav的组合物和方法 |
| CA2967468A1 (en) | 2014-12-16 | 2016-06-23 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| ES2799515T3 (es) | 2015-05-22 | 2020-12-18 | Dmitry Dmitrievich Genkin | ADN extracelular como una diana terapéutica en la neurodegeneración |
| ES2865487T3 (es) | 2015-09-28 | 2021-10-15 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores virales que evaden los anticuerpos |
| WO2017096162A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| MX2018014152A (es) | 2016-05-18 | 2019-03-28 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la enfermedad de huntington. |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| CN109415730A (zh) | 2016-06-13 | 2019-03-01 | 北卡罗来纳大学教堂山分校 | 优化的cln1基因和表达盒以及它们的应用 |
| MA44546B1 (fr) * | 2016-06-15 | 2021-03-31 | Univ California | Virus adéno-associés variants et procédés d'utilisation |
| US20190262373A1 (en) * | 2016-08-16 | 2019-08-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| AU2018261003A1 (en) | 2017-05-05 | 2019-11-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's Disease |
| AU2018261790B2 (en) | 2017-05-05 | 2024-10-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| JP7221275B2 (ja) | 2017-08-03 | 2023-02-13 | ボイジャー セラピューティクス インコーポレイテッド | Ａａｖを送達するための組成物および方法 |
| CA3075656A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| US11491241B2 (en) | 2017-11-07 | 2022-11-08 | The University Of North Carolina At Chapel Hill | Optimized AGA genes and expression cassettes and their use |
| KR20200100735A (ko) * | 2017-12-20 | 2020-08-26 | 오비드 테라퓨틱스 인크. | 발작 장애 치료 시 hM4Di의 용도 |
| JP2021510539A (ja) | 2018-01-16 | 2021-04-30 | シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置 |
| AU2019247191A1 (en) | 2018-04-03 | 2020-10-15 | Ginkgo Bioworks, Inc. | Virus vectors for targeting ophthalmic tissues |
| SG11202009452WA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
| JP2021519581A (ja) | 2018-04-03 | 2021-08-12 | ストライドバイオ，インコーポレイテッド | 抗体を回避するウイルスベクター |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| CN108676097B (zh) * | 2018-05-24 | 2020-01-14 | 北京肽和生物科技有限公司 | 一种靶向肿瘤细胞的嵌合肽或嵌合蛋白及其应用 |
| WO2019241324A1 (en) * | 2018-06-12 | 2019-12-19 | The University Of North Carolina At Chapel Hill | Synthetic liver-tropic adeno-associated virus capsids and uses thereof |
| EP3814513B1 (en) | 2018-06-28 | 2025-04-09 | The University of North Carolina at Chapel Hill | Optimized cln5 genes and expression cassettes and their use |
| IL280300B2 (en) | 2018-08-10 | 2025-06-01 | Univ North Carolina Chapel Hill | Optimized cln7 genes and expression cassettes and their use |
| CN113966399A (zh) | 2018-09-26 | 2022-01-21 | 加州理工学院 | 用于靶向基因疗法的腺相关病毒组合物 |
| AU2019346655B2 (en) | 2018-09-28 | 2025-03-13 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN119684417A (zh) * | 2018-10-02 | 2025-03-25 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| JP2022506066A (ja) | 2018-11-05 | 2022-01-17 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 最適化されたｆｉｇ４遺伝子および発現カセットならびにそれらの使用 |
| WO2020117898A1 (en) * | 2018-12-05 | 2020-06-11 | Abeona Therapeutics Inc. | Recombinant adeno-associated viral vector for gene delivery |
| EP3884057A4 (en) | 2018-12-21 | 2022-09-07 | The University of North Carolina at Chapel Hill | OPTIMIZED GALC GENES AND EXPRESSION CASSETTE AND THEIR USE |
| SG11202111102SA (en) * | 2019-04-29 | 2021-11-29 | Univ Pennsylvania | Novel aav capsids and compositions containing same |
| EP3973059A4 (en) | 2019-05-22 | 2023-10-25 | The University of North Carolina at Chapel Hill | UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE |
| WO2021011368A1 (en) * | 2019-07-12 | 2021-01-21 | Dmitry Dmitrievich Genkin | Treatment of diseases associated with protein misfolding by nervous system expression of an enzyme which has a deoxyribonuclease (dnase) activity |
| US20220380413A1 (en) * | 2019-08-29 | 2022-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Adeno-Associated Viral Vectors for Crossing the Human Blood Brain Barrier |
| EP4025258A4 (en) * | 2019-09-03 | 2023-09-06 | University of Cincinnati | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS |
| CA3157700A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
| CA3164321A1 (en) * | 2020-02-18 | 2021-08-26 | The University Of North Carolina At Chapel Hill | Aav capsid-promoter interactions and cell selective gene expression |
| EP4143305A4 (en) * | 2020-05-01 | 2024-09-11 | The Broad Institute, Inc. | GENETICALLY MODIFIED CENTRAL NERVOUS SYSTEM COMPOSITIONS |
| US20230304033A1 (en) * | 2020-05-04 | 2023-09-28 | The University Of North Carolina At Chapel Hill | Modified adeno-associated virus vectors that evade neutralizing antibodies and uses thereof |
| KR20230034211A (ko) * | 2020-05-05 | 2023-03-09 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 변형된 아데노-관련 바이러스 5 캡시드 및 이의 용도 |
| CN115806596A (zh) * | 2020-05-22 | 2023-03-17 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 腺相关病毒突变体及其应用 |
| EP4591708A2 (en) | 2020-07-08 | 2025-07-30 | Baylor College of Medicine | Gene therapy for stxbp1 encephalopathy |
| US20230287458A1 (en) * | 2020-07-14 | 2023-09-14 | Abeona Therapeutics Inc. | Recombinant adeno-associated viral vectors for multipartite gene delivery |
| US20230159949A1 (en) * | 2020-07-22 | 2023-05-25 | The Broad Institute, Inc. | Engineered muscle targeting compositions |
| JP2023536067A (ja) | 2020-07-23 | 2023-08-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 最適化されたｓｌｃ１３ａ５遺伝子および発現カセットならびにそれらの使用 |
| MX2023001701A (es) * | 2020-08-12 | 2023-03-09 | UCB Biopharma SRL | Terapia genica utilizando constructos de acido nucleico que comprenden secuencias promotoras de la proteina de union a metil cpg 2 (mecp2). |
| CA3189878A1 (en) | 2020-08-19 | 2022-02-24 | Colin O'BANION | Adeno-associated virus vectors for treatment of rett syndrome |
| CN113563430B (zh) * | 2021-07-30 | 2022-05-31 | 上海信致医药科技有限公司 | 用于治疗眼部疾病的基因递送系统及其应用 |
| CA3235632A1 (en) | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| US20250206783A1 (en) * | 2022-03-21 | 2025-06-26 | Capsigen Inc. | Transcription-dependent directed evolution of aav capsids having enhanced tropism |
| WO2025015388A1 (en) * | 2023-07-20 | 2025-01-23 | Children's Medical Research Institute | Modified cardiotropic aav capsid polypeptides and vectors |
| WO2025084951A1 (en) * | 2023-10-16 | 2025-04-24 | Joint Stock Company "Axelgen" | Recombinant genetic construct, adeno-associated virus for the treatment of metachromatic leukodystrophy |
| WO2025147741A1 (en) * | 2024-01-11 | 2025-07-17 | Children's Medical Research Institute | Aav capsids and vectors for transduction of cells |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0322417A1 (en) | 1986-09-08 | 1989-07-05 | Applied Biotechnology, Inc. | Empty viral capsid vaccines |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| JPH04501719A (ja) | 1988-11-10 | 1992-03-26 | インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド | ポリペプチド |
| US5916563A (en) | 1988-11-14 | 1999-06-29 | United States Of America | Parvovirus protein presenting capsids |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| ES2026826A6 (es) | 1991-03-26 | 1992-05-01 | Ercros Sa | Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados. |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| AU730305B2 (en) | 1995-12-15 | 2001-03-01 | Intronn Llc | Therapeutic molecules generated by trans-splicing |
| US6083702A (en) | 1995-12-15 | 2000-07-04 | Intronn Holdings Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| CA2265460A1 (en) | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| EP1082413B1 (en) | 1998-05-28 | 2008-07-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Aav5 vector and uses thereof |
| AU774706B2 (en) | 1998-09-22 | 2004-07-08 | Johns Hopkins University, The | Methods for large-scale production of recombinant AAV vectors |
| AU768729B2 (en) | 1998-11-05 | 2004-01-08 | Trustees Of The University Of Pennsylvania, The | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
| JP2000325085A (ja) | 1999-05-21 | 2000-11-28 | Masafumi Matsuo | デュシェンヌ型筋ジストロフィー治療剤 |
| US6582692B1 (en) | 1999-11-17 | 2003-06-24 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
| AU2001253255A1 (en) | 2000-04-07 | 2001-10-23 | Large Scale Biology Corporation | Compositions and methods for inhibiting gene expression |
| US6653467B1 (en) | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| AU2001268149B2 (en) | 2000-06-01 | 2005-08-18 | University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
| US6727355B2 (en) | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| US6623729B2 (en) | 2001-07-09 | 2003-09-23 | Korea Advanced Institute Of Science And Technology | Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer |
| EP2573170B1 (en) * | 2001-12-17 | 2017-12-20 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor |
| ITRM20020253A1 (it) | 2002-05-08 | 2003-11-10 | Univ Roma | Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche. |
| US20070026076A1 (en) | 2003-02-24 | 2007-02-01 | Tzyy-Choou Wu | Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins |
| PL1620133T3 (pl) | 2003-05-01 | 2016-05-31 | Genzyme Corp | Terapia genowa dla zaburzeń neurometabolicznych |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| ES2874298T3 (es) * | 2003-09-30 | 2021-11-04 | Univ Pennsylvania | Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos |
| JP2007515966A (ja) | 2003-12-23 | 2007-06-21 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 疾患の併用療法のための組成物および方法 |
| FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
| US20070059288A1 (en) | 2005-03-31 | 2007-03-15 | Dinsmore Jonathan H | Treatment for heart disease |
| ES2428218T3 (es) | 2005-04-07 | 2013-11-06 | The Trustees Of The University Of Pennsylvania | Cápsides de AAV rh48 modificadas, composiciones que las contienen y usos de las mismas |
| WO2007089632A2 (en) * | 2006-01-27 | 2007-08-09 | The University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
| CN101506369B (zh) * | 2006-06-21 | 2014-02-12 | 尤尼克尔生物制药股份有限公司 | 具有经修饰的用于在昆虫细胞中产生aav的aav-rep78翻译起始密码子的载体 |
| EP2019143A1 (en) | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
| EP2058401A1 (en) | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| US8632764B2 (en) * | 2008-04-30 | 2014-01-21 | University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| US9415121B2 (en) * | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| DK2826860T3 (en) | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| EP2634253B1 (en) * | 2010-10-27 | 2016-05-11 | Jichi Medical University | Adeno-associated virus virions for transferring genes into neural cells |
| KR101830651B1 (ko) | 2011-01-04 | 2018-02-21 | 엘지전자 주식회사 | 정보 표시 장치 및 그 방법 |
| US9636370B2 (en) * | 2012-09-28 | 2017-05-02 | The University Of North Carolina At Chapel Hill | AAV vectors targeted to oligodendrocytes |
| CN107532173A (zh) * | 2014-11-21 | 2018-01-02 | 北卡罗来纳-查佩尔山大学 | 靶向中枢神经系统的aav载体 |
-
2015
- 2015-11-20 CN CN201580074023.XA patent/CN107532173A/zh active Pending
- 2015-11-20 CN CN202210236316.5A patent/CN114480440A/zh active Pending
- 2015-11-20 EP EP23199459.1A patent/EP4344741A3/en active Pending
- 2015-11-20 AU AU2015349759A patent/AU2015349759B2/en active Active
- 2015-11-20 MX MX2017006652A patent/MX2017006652A/es unknown
- 2015-11-20 BR BR112017010447-4A patent/BR112017010447A2/pt not_active Application Discontinuation
- 2015-11-20 EP EP15861347.1A patent/EP3221453A4/en not_active Ceased
- 2015-11-20 US US15/525,214 patent/US10532110B2/en active Active
- 2015-11-20 JP JP2017525107A patent/JP2017536116A/ja not_active Withdrawn
- 2015-11-20 KR KR1020247013508A patent/KR20240063169A/ko active Pending
- 2015-11-20 CA CA2967393A patent/CA2967393A1/en active Pending
- 2015-11-20 KR KR1020177014680A patent/KR20170086537A/ko not_active Ceased
- 2015-11-20 WO PCT/US2015/061788 patent/WO2016081811A1/en not_active Ceased
- 2015-11-20 RU RU2017121593A patent/RU2727015C2/ru active
-
2017
- 2017-05-03 IL IL252072A patent/IL252072B/en unknown
-
2019
- 2019-06-13 US US16/440,638 patent/US10561743B2/en active Active
-
2020
- 2020-01-13 US US16/741,324 patent/US11491242B2/en active Active
-
2021
- 2021-02-10 JP JP2021019477A patent/JP2021097675A/ja active Pending
-
2022
- 2022-03-04 AU AU2022201540A patent/AU2022201540B2/en active Active
- 2022-09-21 US US17/933,937 patent/US20230263910A1/en active Pending
-
2023
- 2023-06-30 JP JP2023108201A patent/JP2023123765A/ja active Pending
-
2025
- 2025-02-03 JP JP2025015920A patent/JP2025072468A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536116A5 (OSRAM) | ||
| JP7574508B2 (ja) | 血管系を通過する遺伝子移入の方法および組成物 | |
| AU2019200949B2 (en) | High-transduction-efficiency raav vectors, compositions, and methods of use | |
| CN112566923B (zh) | 合成嗜肝性腺相关病毒衣壳及其用途 | |
| JP2023123765A5 (OSRAM) | ||
| JP2022001064A5 (OSRAM) | ||
| CN110770346A (zh) | 多倍体腺相关病毒载体及其制备和使用方法 | |
| CN111727243A (zh) | 用于跨越血-脑屏障递送病毒载体的方法和组合物 | |
| CA3081705A1 (en) | Methods and compositions for circular rna molecules | |
| JP2011101646A5 (OSRAM) | ||
| KR20180091863A (ko) | 임상적 사용에 적합한 무혈청 현탁 세포 배양 시스템에서 재조합 아데노-관련 바이러스(aav) 벡터를 생성하기 위한 확장가능한 방법 | |
| WO2017192750A1 (en) | Recombinant adeno-associated viral vectors | |
| JP2014507145A (ja) | 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法 | |
| JP2008545406A5 (OSRAM) | ||
| JP7524166B2 (ja) | 脳に指向性を有するａａｖ変異体 | |
| JP2017529395A5 (OSRAM) | ||
| CN115960921A (zh) | 一组肝靶向新型腺相关病毒的获得及其应用 | |
| JP2024515626A (ja) | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン | |
| KR20110098261A (ko) | 아데노 연관 바이러스 혈청형 벡터의 대량 생산 및 정제 방법 | |
| Shen et al. | Significant Enhancement of Adeno‐Associated Virus Vector Yield for Gene Therapy Using Multidimensional Optimization Strategies | |
| WO2025065890A1 (zh) | 一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用 | |
| HK40048077B (zh) | 合成嗜肝性腺相关病毒衣壳及其用途 | |
| HK40062349B (zh) | 具有脑靶向特性的aav突变体 | |
| HK40022719B (zh) | 多倍体腺相关病毒载体及其制备和使用方法 | |
| NZ731673B2 (en) | Aav vectors targeted to the central nervous system |